Overview

Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

Status:
Recruiting

Trial end date:
2026-12-01

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Coordination Pharmaceuticals, Inc.

Collaborator:

University of Illinois at Chicago

Treatments:

Immune Checkpoint Inhibitors
Nivolumab
Pembrolizumab